Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations for Older Adults With Cancer (PACE-70)

What this Trial Is About

Researchers are studying the use of the Practical Geriatric Assessment (PGA) to improve cancer care for adults aged 70 and older who have advanced or metastatic solid tumors. This study focuses on how the PGA, designed to be easier to use in real-world settings, affects chemotherapy dose adjustments and patient outcomes. It also explores links between PGA results, body composition from CT scans, and physical activity measured by FitBit to better understand treatment toxicity and other clinical effects in older adults with cancer. The PGA is completed by patients either before or during their initial oncology visit using the electronic health record system, with staff assistance if needed. The assessment results are shared with clinical teams via alerts that highlight geriatric impairments and provide care recommendations. Participants receive standard palliative-intent systemic therapy, and the study tracks the rate of PGA completion and chemotherapy dose changes based on the assessment. A subgroup will participate in additional monitoring with FitBit devices and body composition analysis through CT scans. During the study, participants will complete the PGA and their clinical teams will use the results to guide treatment decisions. Researchers will collect data on chemotherapy dose modifications, toxicity, hospitalizations, and survival. Clinician feedback on using the PGA will be gathered through interviews. Participation involves completing surveys, wearing a FitBit for step tracking (for some), and undergoing routine CT scans. The study runs through October 2026, with ongoing monitoring and data collection to help tailor cancer care for older adults.

Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)